Description
Michael S. Lloyd, MD, FHRS of Emory University discusses the Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences. He is joined by guests Jason G. Andrade, MD, FHRS of Vancouver General Hospital and Stefan H. Hohnloser, MD, FHRS of J. W. Goethe University.
Learning Objectives
- Compare the impact of early versus delayed atrial fibrillation catheter ablation in the context of this study.
Article Authors and Podcast Contributors
Article Authors
Jonathan M. Kalman, MBBS, PhD; Ahmed M Al-Kaisey MBChB; Ramanathan Parameswaran, MBBS, PhD; Joshua Hawson, MBBS; Robert D. Anderson, MBBS, PhD; Michael Lima, David Chieng, MBBS; Stephen A. Joseph, MBBS, PhD; Alex McLellan, MBBS, PhD; Joseph B. Morton, MBBS, PhD; Paul B. Sparksa, MBBS, PhD; Geoffrey Lee, MBBS, PhD; Prashanthan Sanders, MBBS, PhD; Peter M. Kistler, MBBS, PhD
Podcast Contributors
Michael S. Lloyd, MD, FHRS of Emory University
Jason G. Andrade, MD, FHRS of Vancouver General Hospital
Stefan H. Hohnloser, MD, FHRS of J. W. Goethe University
Disclosure Policy
All relevant financial relationships have been mitigated.
Host Disclosure(s):
M. Lloyd: Honraria/Speaking/Consulting Fee: Medtronic, Baylis Medical Company, Boston Scientific
Contributor Disclosure(s):
J. Andrade: Honoraria/Speaking/Consulting Fee: Medtronic, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Servier, Baylis Medical Company, Biosense Webster
S. Hohnloser: Honoraria/Speaking/Consulting Fee: Boehringer Ingelheim, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Daiichi, Pfizer Inc., Zoll Medical Corporation, Sanofi
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.